Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.

Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study. Consecutive ambulatory or hospitalized patients aged ≥ 50 years...

Descripción completa

Detalles Bibliográficos
Autores: García-Pavía, Pablo, García-Pinilla, José Manuel, Lozano-Bahamonde, Ainara, Yun, Sergi, García-Quintana, Antonio, Gavira-Gómez, Juan José, Aibar-Arregui, Miguel Ángel, Barge-Caballero, Gonzalo, Núñez Villota, Julio, Bernal, Laura, Tarilonte, Patricia
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/25889
Acceso en línea:https://hdl.handle.net/20.500.12105/25889
Access Level:acceso abierto
Palabra clave:Amiloidosis cardiaca
Amiloidosis cardiaca por transtirretina
Cardiac amyloidosis
Fracción de eyección conservada
Heart failure
Hipertrofia del ventrículo izquierdo
Insuficiencia cardiaca
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Prevalencia
Transthyretin
Transthyretin cardiac amyloidosis
Transtirretina
id ES_9ee410c548bccbdfd895fa9b818b3a3b
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/25889
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.García-Pavía, PabloGarcía-Pinilla, José ManuelLozano-Bahamonde, AinaraYun, SergiGarcía-Quintana, AntonioGavira-Gómez, Juan JoséAibar-Arregui, Miguel ÁngelBarge-Caballero, GonzaloNúñez Villota, JulioBernal, LauraTarilonte, PatriciaAmiloidosis cardiacaAmiloidosis cardiaca por transtirretinaCardiac amyloidosisFracción de eyección conservadaHeart failureHipertrofia del ventrículo izquierdoInsuficiencia cardiacaLeft ventricular hypertrophyPreserved ejection fractionPrevalencePrevalenciaTransthyretinTransthyretin cardiac amyloidosisTranstirretinaTransthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study. Consecutive ambulatory or hospitalized patients aged ≥ 50 years with HFpEF and left ventricle hypertrophy ≥ 12mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3±5.2 years, mean left ventricle ejection fraction of 60.3±7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II (48.4%) or III (46.8%). Besides being older than non-ATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [1141-4796] pg/mL; P=.003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P=.085). A ∼7% (4/56) of the patients exhibited a genetic variant (ATTRv). This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years.Elsevier20242024-12-1720242024-07-3120242024-07-31research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/25889reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/258892026-06-12T12:43:37Z
dc.title.none.fl_str_mv Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
title Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
spellingShingle Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
García-Pavía, Pablo
Amiloidosis cardiaca
Amiloidosis cardiaca por transtirretina
Cardiac amyloidosis
Fracción de eyección conservada
Heart failure
Hipertrofia del ventrículo izquierdo
Insuficiencia cardiaca
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Prevalencia
Transthyretin
Transthyretin cardiac amyloidosis
Transtirretina
title_short Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
title_full Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
title_fullStr Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
title_full_unstemmed Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
title_sort Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
dc.creator.none.fl_str_mv García-Pavía, Pablo
García-Pinilla, José Manuel
Lozano-Bahamonde, Ainara
Yun, Sergi
García-Quintana, Antonio
Gavira-Gómez, Juan José
Aibar-Arregui, Miguel Ángel
Barge-Caballero, Gonzalo
Núñez Villota, Julio
Bernal, Laura
Tarilonte, Patricia
author García-Pavía, Pablo
author_facet García-Pavía, Pablo
García-Pinilla, José Manuel
Lozano-Bahamonde, Ainara
Yun, Sergi
García-Quintana, Antonio
Gavira-Gómez, Juan José
Aibar-Arregui, Miguel Ángel
Barge-Caballero, Gonzalo
Núñez Villota, Julio
Bernal, Laura
Tarilonte, Patricia
author_role author
author2 García-Pinilla, José Manuel
Lozano-Bahamonde, Ainara
Yun, Sergi
García-Quintana, Antonio
Gavira-Gómez, Juan José
Aibar-Arregui, Miguel Ángel
Barge-Caballero, Gonzalo
Núñez Villota, Julio
Bernal, Laura
Tarilonte, Patricia
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Amiloidosis cardiaca
Amiloidosis cardiaca por transtirretina
Cardiac amyloidosis
Fracción de eyección conservada
Heart failure
Hipertrofia del ventrículo izquierdo
Insuficiencia cardiaca
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Prevalencia
Transthyretin
Transthyretin cardiac amyloidosis
Transtirretina
topic Amiloidosis cardiaca
Amiloidosis cardiaca por transtirretina
Cardiac amyloidosis
Fracción de eyección conservada
Heart failure
Hipertrofia del ventrículo izquierdo
Insuficiencia cardiaca
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Prevalencia
Transthyretin
Transthyretin cardiac amyloidosis
Transtirretina
description Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study. Consecutive ambulatory or hospitalized patients aged ≥ 50 years with HFpEF and left ventricle hypertrophy ≥ 12mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3±5.2 years, mean left ventricle ejection fraction of 60.3±7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II (48.4%) or III (46.8%). Besides being older than non-ATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [1141-4796] pg/mL; P=.003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P=.085). A ∼7% (4/56) of the patients exhibited a genetic variant (ATTRv). This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-12-17
2024
2024-07-31
2024
2024-07-31
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/25889
url https://hdl.handle.net/20.500.12105/25889
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414864536993792
score 15.811543

Similares en LA Referencia